Actively Recruiting
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Patients With Large B-Cell Lymphoma
Led by The Clatterbridge Cancer Centre NHS Foundation Trust · Updated on 2026-01-12
800
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying large B-cell lymphoma (LBCL), a cancer affecting the lymphatic system where certain white blood cells grow uncontrollably. This research focuses on patients who cannot tolerate standard full-dose chemo-immunotherapy treatments due to frailty or who have relapsed or not responded to initial treatments. The goal is to collect real-world data on how these patients are managed and their outcomes to improve understanding and future care for LBCL. The study observes two groups: those with LBCL who need treatment but are unsuitable for standard full-dose therapies, and those with relapsed or refractory LBCL after prior treatment. The study does not test new drugs but gathers information from patients receiving various treatments in routine care. Retrospective data from patients who started treatment within six months before enrollment may also be included. Participants will provide information through medical records and follow-up over time. Researchers will monitor progression-free survival at 12 months as the primary outcome. The study is observational, so no specific treatments are assigned, but data on treatments and responses will be collected to help guide future research and improve care. Enrollment begins in October 2024 and continues through 2028.
CONDITIONS
Brief Title
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females aged 16 years or older at enrollment
- Ability to understand and sign written informed consent
- Histologically confirmed large B-cell non-Hodgkin's lymphoma (LBCL) according to WHO 2016 classification
- For Cohort A: LBCL patients unfit for full dose R-CHOP or Pola-R-CHP, including specific LBCL subtypes and de novo transformed indolent B-cell lymphomas
- For Cohort B: LBCL patients with relapsed or refractory disease after frontline chemo-immunotherapy, including CAR-T therapy recipients
- Patients on other trials or previously in Cohort A who now have relapsed disease can join Cohort B
- Data can be entered retrospectively for patients who started treatment less than 6 months before enrollment
You will not qualify if you...
- Patients treated more than 6 months before trial enrollment (Cohort B)
- Patients eligible for full dose R-CHOP or Pola-R-CHP (Cohort A)
- Patients with central nervous system (CNS) lymphoma
- Lymphomas associated with immune suppression or dysregulation, such as post-transplant lymphoproliferative disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months
Participants who undergo routine care for large B-cell lymphoma are observed and data are collected.
1 to 2 visits depending on cohort assignment
Trial Site Locations
Total: 1 location
1
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, Merseyside, United Kingdom, L78YA
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here